Shiqian Chen

Dalian Medical University — China

Medicine · Health Sciences

9h-index400citations19works20.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(13), Pancreatic function and diabetes(11), Receptor Mechanisms and Signaling(11), Metabolism, Diabetes, and Cancer(3), Liver Disease Diagnosis and Treatment(2)

Publications19 total

Spatially diffuse cAMP signalling with oppositely biased GLP-1 receptor agonists in β-cells despite differences in receptor localisation
Molecular Metabolism·2025· 1 citedOpen Access
5-Hydroxytryptamine promotes non-small cell lung cancer metastasis via the SNRPG/WT1/CDK14 Axis
Molecular Biomedicine·2025Open Access
Metabolic State Determines Central and Peripheral Mechanisms of Liraglutide-Enhanced Insulin Secretion
2024Open Access
Computational modelling of dynamic cAMP responses to GPCR agonists for exploration of GLP-1R ligand effects in pancreatic β-cells and neurons
Cellular Signalling·2024· 2 citedOpen Access
Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)
International Journal of Oncology·2024· 94 citedOpen Access
New roles of tumor-derived exosomes in tumor microenvironment
Chinese Journal of Cancer Research·2024· 27 citedOpen Access
Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists
Diabetes Obesity and Metabolism·2023· 31 citedOpen Access
GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification
Nature Genetics·2023· 93 citedOpen Access
Author response for "Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists"
2023
Author response for "Abolishing β‐arrestin recruitment is necessary for the full metabolic benefits of G protein‐biased glucagon‐like peptide‐1 receptor agonists"
2023
Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells
Endocrinology·2023· 44 citedOpen Access
The Central-Versus Peripheral-Mediated Effects of Liraglutide Enhancement on Insulin Secretion is Dependent on the Stage of Diabetes
SSRN Electronic Journal·2023Open Access
An examination of the divergent spatiotemporal signaling of GLP-1R <i>versus</i> GIPR in pancreatic beta cells
2022· 1 citedOpen Access
Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1
Biochemical Pharmacology·2021· 13 citedOpen Access
Random glucose GWAS in 493,036 individuals provides insights into diabetes pathophysiology, complications and treatment stratification
2021· 9 citedOpen Access
Evaluation of efficacy- <i>versus</i> affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1
2021Open Access
Ligand-Specific Factors Influencing GLP-1 Receptor Post-Endocytic Trafficking and Degradation in Pancreatic Beta Cells
International Journal of Molecular Sciences·2020· 44 citedOpen Access
The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists
ACS Pharmacology & Translational Science·2020· 40 citedOpen Access
The influence of peptide context on signalling and trafficking of glucagon-like peptide-1 receptor biased agonists
2020· 1 citedOpen Access

Frequent Co-authors

Ben Jones(16), Alejandra Tomás(13), Tricia Tan(11), Johannes Broichhagen(8), Stephen R. Bloom(8), Ivan R. Corrêa(7), David J. Hodson(6), Victoria Salem(5), Philip Pickford(5), Guy A. Rutter(5), Iona Davies(5), Yusman Manchanda(4), Jinzhe Sun(3), Dan Zang(3), Alessia David(3), Cornelia M. van Duijn(3), Zijian Fang(3), Stavroula Bitsi(3), Charlotte E. Hinds(3), Ellie Peace(3)